The Latest Breaking News from Teleflex

Teleflex is poised to post its fourth-quarter earnings by the end of next month, and analysts are expecting a modest-double-digit rise in its earnings.

Although Teleflex has underperformed relative to the healthcare sector over the past year, Wall Street analysts maintain a moderately optimistic outlook on the stock’s prospects.

MINNEAPOLIS — Medtronic is weighing its next steps after losing another round in a long-running patent dispute with med-tech competitor Teleflex Inc.

Teleflex Inc (NYSE: TFX) hosted its Investor Day and issued plans for 2023-2025. RBC Capital Markets believe TFX is a stronger company delivering stable revenue growth in the M-HSDs, margin expansion, double-digit EPS growth, and strong FCF. 

Over the past 3 months, 12 analysts have published their opinion on Teleflex (NYSE:TFX) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

Despite the prevailing bearish investor sentiment, the healthcare industry is expected to continue growing amid an increase in global chronic diseases, rapid medical advancements, and an aging population. The stocks of quality healthcare companies Bausch Health (BHC), Teleflex (TFX), Abcam (ABCM), and Integra LifeSciences (IART) are currently trading near their…

Upgrades

According to Benzinga Pro, during Q1, Teleflex (NYSE:TFX) earned $77.14 million, a 39.77% increase from the preceding quarter. Teleflex's sales decreased to $641.72 million, a 15.78% change since Q4.

RBC Capital Markets says that Teleflex Incorporated (NYSE: TFX) delivered a Q1 beat and maintained 2022 guidance.